SOPHiA GENETICS SA
All Connections
6 total
All Connections
6 totalSOPHiA GENETICS SA is PSC (person with significant control) of SOPHIA GENETICS LIMITED with 75-100% ownership, voting rights, and right to appoint/remove directors. PSC filing date: April 6, 2016.
SOPHiA GENETICS SA wholly owns SOPHIA GENETICS, INC. (Delaware), which serves as registered agent for the parent in the US and holds active DoD bioinformatics contracts. SAM-registered entity since December 2017.
Perceptive Credit Holdings IV, LP is lender and warrant holder under the $75M credit facility. SOPHiA GENETICS SA must register warrant shares (up to 675,000 total) for resale within 30 business days of each draw. Current F-3 (333-293970) covers 75,000 Second Amendment warrant shares at $5.1829/share.
Jurgi Camblong is co-founder, Director, and CEO of SOPHiA GENETICS SA since March 2011. He holds 3,307,325 shares (largest insider position) and is transitioning to Executive Chairman effective July 1, 2026.
Balderton Capital VI, S.L.P. (BCVI) is a 5.2% shareholder of SOPHiA GENETICS SA as of December 31, 2025 per Schedule 13G/A (Amendment No. 3, filed 2026-02-11). Long-term investor since at least Series B. Manager: Petr Klimo of BCVI Sarl.
Tomer Berkovitz serves as a board director of SOPHiA GENETICS SA and is Managing Partner at aMoon Fund, an Israeli life sciences investor. He filed Form 3 on the HFIA effective date with 0 direct shares but disclosed derivative securities.
All Findings
6 total
All Findings
6 totalfinancial (3)
Perceptive Credit Holdings IV LP holds warrants for up to 675,000 SOPH shares as kicker on a $75M term loan facility at SOFR+6.25%. All active exercise prices ($4.9992–$5.1829) are above current stock price (~$4.70).
Perceptive Credit Holdings IV, LP holds warrants for up to 675,000 ordinary shares of SOPHiA GENETICS SA across five tranches: Tranche A (200,000 @ $4.9992, exercisable through May 2034), Tranche B (200,000 @ $4.9992, exercisable through June 2035), Second Amendment / 2A (75,000 @ $5.1829, exercisable through January 2036), Tranche C (100,000, price = 5-day VWAP on draw, contingent on Tranche C draw), and Tranche D (100,000, price = 5-day VWAP, conditioned on TTM revenue > $85M). All active warrants (475,000 shares) are currently out-of-the-money vs current price ~$4.70. Total credit facility: up to $75M at Term SOFR + 6.25%, maturing 2029.
SOPHiA GENETICS FY2025: $77.27M revenue (+18.6%), IFRS net loss $19.2M. EGC status expires Dec 31, 2026. ATM program raised $14.4M in Q1 2026 alone. 2026 guidance $92–94M with adj. EBITDA breakeven approach.
FY2025 20-F (filed 2026-03-03): Revenue $77.27M (+18.6% YoY); IFRS net loss $19.2M (+27% YoY); adjusted EBITDA loss $9.9M (+9% YoY); gross margin 67.7% reported / 73.9% adjusted. 2026 guidance: $92–94M revenue; approach adj. EBITDA breakeven by end of 2026; positive adj. EBITDA H2 2027. EGC status expires December 31, 2026. ATM program raised $15.5M total ($14.4M in Q1 2026 alone). Shares outstanding as of March 2026: 68,486,338.
The March 2026 F-3/424B3 (333-293970) registers 75,000 warrant shares for lender Perceptive Credit Holdings IV, LP — not an insider resale shelf. Three older F-3 registrations (333-280060, 333-289266, 333-289270) also on file.
The F-3 (Registration No. 333-293970) and 424B3 filed by SOPHiA GENETICS SA in March 2026 register only 75,000 ordinary shares for resale by Perceptive Credit Holdings IV, LP. These are warrant exercise shares from the Second Amendment to the credit agreement (January 23, 2026), exercise price $5.1829/share, exercisable through January 23, 2036. The company is contractually obligated to file this registration. This is NOT an insider secondary resale registration.
governance (1)
SOPHiA GENETICS CEO transition: Jurgi Camblong → Ross Muken effective July 1, 2026. Camblong to become Executive Chairman (subject to AGM June 2026). New CFO Cardoza (Nov 2024) and new CSalesO Puylaert (Jan 2026) also signal leadership renewal.
SOPHiA GENETICS announced CEO transition on January 12, 2026: Jurgi Camblong (co-founder, CEO since 2011) will transition to Executive Chairman effective July 1, 2026 (subject to AGM election in June 2026); Ross Muken (President since May 2024, previously CFO and COO) will become CEO. Camblong will remain a full-time executive focused on strategic initiatives and technology innovation. George Cardoza joined as CFO in November 2024. Kevin Puylaert appointed Chief Sales Officer effective January 2026.
regulatory (2)
SOPHiA GENETICS SA filed 15 Form 3s on HFIA effective date (2026-03-18), the first-ever Section 16 disclosures by company insiders. CEO Jurgi Camblong holds 3,307,325 shares; total insider holdings across 10 officers and 5 directors disclosed.
SOPHiA GENETICS SA filed 15 Form 3 initial beneficial ownership statements on the HFIA effective date (2026-03-18), the first-ever Section 16 disclosures by the company's insiders. CEO Jurgi Camblong disclosed 3,307,325 shares; CSO Zhenyu Xu disclosed 537,724 shares; CLO Daan van Well disclosed 261,922 shares. Five board-only directors disclosed holdings between 97,276 and 503,136 shares. Tomer Berkovitz (aMoon Fund) disclosed 0 direct shares.
All 8 C-suite officers sold shares on 2026-03-19 under pre-established 10b5-1 plans for RSU tax withholding. Sales triggered by RSU vesting on HFIA effective date (2026-03-18). Not discretionary selling.
All 8 C-suite officers sold shares on 2026-03-19, one day after HFIA Form 3s were due. Form 144 filings confirm all sales were RSU vesting tax-withholding under Rule 10b5-1 plans administered by Morgan Stanley Smith Barney LLC Executive Financial Services. Nature of acquisition in each Form 144: 'Restricted Stock Units / Issuer', acquisition date 2026-03-18, payment date 2026-03-18. Aggregate proceeds across all 8 officers estimated at approximately $38,000–$43,000 — de minimis relative to holdings.